|
WO2021064197A1
|
|
Isolated polypeptide and polypeptide complexes for prevention, alleviation and/or treatment of hcv infections
|
|
WO2021053235A1
|
|
Method for controllable growth of elongated nanostructures
|
|
WO2021048283A1
|
|
Method for promoting weight loss by administering a diet rich in arabinoxylan oligosaccharides
|
|
WO2021023844A1
|
|
Compositions and methods for predicting and promoting weight loss in patients with low amy1 copy numbers
|
|
WO2020260684A1
|
|
An optical sensor
|
|
WO2020259787A1
|
|
Treatment of cns disorders with sleep disturbances
|
|
WO2021008840A1
|
|
Fusion toxin proteins for treatment of diseases related to cmv infections
|
|
WO2020216777A1
|
|
New class of antibiotics having low mic-values towards different strains of bacteria
|
|
WO2020208093A1
|
|
Cysteine derivatives for treatment and prevention of bacterial infections
|
|
WO2020201267A1
|
|
Identification of pan-gamma secretase inhibitor (pan-gsi) theranostic response signatures for cancers
|
|
WO2020151795A1
|
|
A class of small-molecule compounds and their prodrugs for intervention with camk2a, and their use in acute brain injuries and central hypersomnias
|
|
WO2020127958A1
|
|
Covalent inhibitors of enzyme targets with specific tyrosine-containing motifs
|
|
WO2020120565A1
|
|
Magnetic field sensing device for high-strength magnetic fields
|
|
WO2020120480A1
|
|
Vasodilators for use in the treatment of a retinal ischemic disorder
|
|
WO2020115113A1
|
|
Dual agonist glp-1 and neurotensin fusion peptide
|
|
WO2020108720A1
|
|
Novel tetrazine compounds for in vivo imaging
|
|
WO2020109546A1
|
|
Treatment of cardiovascular diseases
|
|
WO2020104578A2
|
|
Modulators of free fatty acid receptor 1 and their use for treatment of diseases
|
|
WO2020083916A1
|
|
Virally expressed inhibitors of pdz domains, such as pick1 and uses thereof
|
|
WO2020083905A1
|
|
Inhibitors of pick1 and uses thereof
|
